OPKO Health, Inc. (NASDAQ:OPK) Files An 8-K Regulation FD DisclosureItem 7.01.
The information set forth under Item 7.01 of this Current Report on Form 8-K is incorporated herein by reference to this Item 7.01.
The information contained in Item 7.01 to this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing by the Company under the Act, unless expressly stated otherwise.
Members of management for OPKO Health, Inc. (the “Company”), a Delaware corporation, prepared a slide deck to be presented at the 2017 Wells Fargo Healthcare Conference in Boston on September7, 2017. Due to the possible effects of Hurricane Irma on South Florida, the Company’s management will no longer be presenting at the conference and is instead filing an updated management presentation with this Form 8-K. The Company’s management intends to use a similar presentation at the Cantor Fitzgerald Global Healthcare Conference on Monday, September25, 2017, the Ladenburg Thalmann 2017 Healthcare Conference on Tuesday, September26, 2017, and the 10th Annual Barrington Fall Investment Conference on Wednesday, September27, 2017.
A copy of the Company’s updated corporate presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The corporate presentation is also available on the OPKO website at www.opko.com under Investor Relations. The information contained on OPKO’s website shall not be deemed part of this report.
| Item 7.01 | Financial Statements and Exhibits. |
(d)Exhibits
|
Exhibit No. |
Description |
| 99.1 | Corporate Presentation of OPKO Health, Inc. |
Opko Health, Inc. ExhibitEX-99.1 2 d410273dex991.htm EX-99.1 EX-99.1 September 2017 NASDAQ: OPK Diagnostics & Pharmaceuticals for Large Markets with Unmet Needs Exhibit 99.1 FORWARD-LOOKING statementS This presentation contains “forward-looking statements,…To view the full exhibit click here
About OPKO Health, Inc. (NASDAQ:OPK)
OPKO Health, Inc. (OPKO) is a healthcare company. The Company operates through two segments: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations. The Company’s diagnostics business includes Bio-Reference Laboratories (Bio-Reference), which is a clinical laboratory with a genetic testing business, including the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. Its pharmaceutical business includes OPKO Biologics, which features hGH-CTP, a once-weekly human growth hormone injection (in Phase III and partnered with Pfizer), and a longer acting Factor VIIa drug for hemophilia (Phase IIa). In addition to its pharmaceutical and diagnostic development programs, it owns pharmaceutical platforms in Ireland, Chile, Spain and Mexico.